Home > Insider Trading > Filing (0001209191-20-051611)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1438533	Retrophin Inc.	RTRX	Pharmaceutical Preparations (2834)	262383102

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1763494	M Eric Dube	3721 Valley Centre Dr, #200 San Diego CA 92130	Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2020-09-18	25,000	$0.00	102,500	No	4	A	Direct
Common Stock	Acquisiton	2020-09-18	3,000	$0.00	105,500	No	4	A	Direct
Common Stock	Disposition	2020-09-21	9,240	$19.28	96,260	No	4	S	Direct
Common Stock	Disposition	2020-09-21	1,565	$19.29	94,695	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	A	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

On January 4, 2019, the reporting person was granted performance restricted stock units (PRSUs) covering 50,000 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On September 18, 2020, a portion of the PRSUs vested upon the Issuer's confirmation that the first 280 patients in the sparsentan PROTECT Phase 3 Study had been enrolled.
On May 9, 2019, the reporting person was granted performance restricted stock units (PRSUs) covering 6,000 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On September 18, 2020, a portion of the PRSUs vested upon the Issuer's confirmation that the first 280 patients in the sparsentan PROTECT Phase 3 Study had been enrolled.
Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested performance restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.